23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
The Special Committee of 23andMe's Board of Directors (Nasdaq: ME) has unanimously rejected a non-binding acquisition proposal from CEO Anne Wojcicki. The proposal aimed to acquire all outstanding shares not owned by Wojcicki and her affiliates for $0.41 per share.
This new offer represents an 84% decrease from the previous joint non-binding proposal of $2.53 per share submitted on February 20, 2025. The proposal was disclosed in an amended Schedule 13D filing with the SEC.
Moelis & Company and Goodwin Procter LLP are serving as financial and legal advisors respectively to the Special Committee, which has stated it will not provide further comments until required.
Il Comitato Speciale del Consiglio di Amministrazione di 23andMe (Nasdaq: ME) ha respinto all'unanimità una proposta di acquisizione non vincolante presentata dal CEO Anne Wojcicki. La proposta mirava ad acquisire tutte le azioni in circolazione non possedute da Wojcicki e dai suoi affiliati per $0,41 per azione.
Questa nuova offerta rappresenta una riduzione dell'84% rispetto alla precedente proposta congiunta non vincolante di $2,53 per azione presentata il 20 febbraio 2025. La proposta è stata divulgata in un deposito modificato del Schedule 13D presso la SEC.
Moelis & Company e Goodwin Procter LLP stanno fungendo rispettivamente da consulenti finanziari e legali per il Comitato Speciale, che ha dichiarato che non fornirà ulteriori commenti fino a quando non sarà necessario.
El Comité Especial de la Junta Directiva de 23andMe (Nasdaq: ME) ha rechazado unánimemente una propuesta de adquisición no vinculante presentada por la CEO Anne Wojcicki. La propuesta tenía como objetivo adquirir todas las acciones en circulación no poseídas por Wojcicki y sus afiliados por $0.41 por acción.
Esta nueva oferta representa una disminución del 84% respecto a la propuesta conjunta no vinculante anterior de $2.53 por acción presentada el 20 de febrero de 2025. La propuesta fue divulgada en un depósito modificado del Schedule 13D ante la SEC.
Moelis & Company y Goodwin Procter LLP están actuando como asesores financieros y legales, respectivamente, para el Comité Especial, que ha declarado que no proporcionará más comentarios hasta que sea necesario.
23andMe의 이사회 특별위원회(Nasdaq: ME)는 CEO 앤 우오츠키가 제안한 비구속 인수 제안을 전원 일치로 거부했습니다. 이 제안은 우오츠키와 그녀의 계열사가 소유하지 않은 모든 유통 주식을 주당 $0.41에 인수하는 것을 목표로 했습니다.
이번 새로운 제안은 2025년 2월 20일에 제출된 주당 $2.53의 이전 공동 비구속 제안에 비해 84% 감소한 것입니다. 이 제안은 SEC에 수정된 Schedule 13D 제출에서 공개되었습니다.
Moelis & Company와 Goodwin Procter LLP는 각각 특별위원회의 재무 및 법률 자문 역할을 하고 있으며, 특별위원회는 필요할 때까지 추가적인 논평을 제공하지 않을 것이라고 밝혔습니다.
Le Comité Spécial du Conseil d'Administration de 23andMe (Nasdaq: ME) a rejeté à l'unanimité une proposition d'acquisition non contraignante de la part de la CEO Anne Wojcicki. La proposition visait à acquérir toutes les actions en circulation non détenues par Wojcicki et ses affiliés pour 0,41 $ par action.
Cette nouvelle offre représente une diminution de 84% par rapport à la précédente proposition conjointe non contraignante de 2,53 $ par action soumise le 20 février 2025. La proposition a été divulguée dans un dépôt modifié du Schedule 13D auprès de la SEC.
Moelis & Company et Goodwin Procter LLP servent respectivement d'experts financiers et juridiques pour le Comité Spécial, qui a déclaré qu'il ne fera pas de commentaires supplémentaires jusqu'à ce que cela soit nécessaire.
Der Sonderausschuss des Vorstands von 23andMe (Nasdaq: ME) hat ein einstimmig abgelehntes nicht verbindliches Übernahmeangebot von CEO Anne Wojcicki. Das Angebot zielte darauf ab, alle ausstehenden Aktien, die nicht im Besitz von Wojcicki und ihren verbundenen Unternehmen sind, zu einem Preis von 0,41 $ pro Aktie zu erwerben.
Dieses neue Angebot stellt einen Rückgang von 84% im Vergleich zu dem vorherigen gemeinsamen nicht verbindlichen Angebot von 2,53 $ pro Aktie dar, das am 20. Februar 2025 eingereicht wurde. Das Angebot wurde in einer geänderten Einreichung des Schedule 13D bei der SEC offengelegt.
Moelis & Company und Goodwin Procter LLP fungieren jeweils als Finanz- und Rechtsberater für den Sonderausschuss, der erklärt hat, dass er keine weiteren Kommentare abgeben wird, bis dies erforderlich ist.
- None.
- CEO's acquisition offer decreased 84% to $0.41 from $2.53 per share
- Special Committee unanimously rejected the acquisition proposal
- Previous co-bidder no longer part of the acquisition attempt
SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of capital stock of 23andMe not owned by Ms. Wojcicki and her affiliates (or any other stockholders that she invites to “roll over” their current equity ownership) for cash consideration of
The Special Committee has reviewed Ms. Wojcicki’s acquisition proposal in consultation with its financial and legal advisors, and has unanimously determined to reject the proposal. Moelis & Company LLC is serving as financial advisor and Goodwin Procter LLP is serving as legal advisor to the Special Committee.
The Special Committee does not intend to comment further on these matters until it determines that additional disclosure is appropriate or required by law.
About 23andMe
23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit www.23andme.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, the ability to complete a transaction as a result of the strategic alternatives process being conducted by the Special Committee, the Company’s ability to raise additional capital or otherwise improve its liquidity position, and the Company’s ability to continue as a going concern. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
FAQ
What is the current acquisition offer price for 23andMe (ME) stock?
Why did 23andMe's Special Committee reject the acquisition proposal?
How much did 23andMe's (ME) acquisition offer decrease from the February 20, 2025 proposal?
Who are the advisors for 23andMe's Special Committee in the acquisition proposal?
